| scholarly article | Q13442814 |
| P2093 | author name string | Apostolos Koffas | |
| Grace E Dolman | |||
| Patrick Tf Kennedy | |||
| P2860 | cites work | Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations | Q26752690 |
| Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) | Q26801716 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. | Q30434625 | ||
| Chronic hepatitis B. | Q34002160 | ||
| 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host | Q34390072 | ||
| An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening | Q35584844 | ||
| Present and future therapies of hepatitis B: From discovery to cure | Q36378278 | ||
| Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies | Q36752181 | ||
| Improving testing for hepatitis B before treatment with rituximab | Q37229995 | ||
| Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. | Q37801513 | ||
| Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy | Q37862588 | ||
| Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. | Q38056581 | ||
| Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs | Q38155954 | ||
| Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. | Q38194708 | ||
| American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy | Q38275214 | ||
| American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Q38275215 | ||
| HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT. | Q38427424 | ||
| EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection | Q38692559 | ||
| Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions | Q38755178 | ||
| Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis | Q38765053 | ||
| Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. | Q38778109 | ||
| Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. | Q40045559 | ||
| Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. | Q40047815 | ||
| Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. | Q40575142 | ||
| Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis. | Q40801411 | ||
| High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma | Q41152880 | ||
| Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. | Q41252998 | ||
| New insights in the management of chronic hepatitis B. | Q41369727 | ||
| Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation | Q42233865 | ||
| Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. | Q42257388 | ||
| Immunosuppression in Patients with Chronic Hepatitis B. | Q42764680 | ||
| FDA: Increased HBV reactivation risk with ofatumumab or rituximab | Q43837340 | ||
| Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy | Q45326378 | ||
| Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. | Q45382228 | ||
| Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues | Q46856544 | ||
| The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection | Q47096774 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| P304 | page(s) | 212-218 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Clinical Medicine | Q5133773 |
| P1476 | title | Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians | |
| P478 | volume | 18 |
Search more.